Martin Dossenbach

Summary

Affiliation: Eli Lilly and Company
Country: USA

Publications

  1. pmc Clinical consequences of switching from olanzapine to risperidone and vice versa in outpatients with schizophrenia: 36-month results from the Worldwide Schizophrenia Outpatients Health Outcomes (W-SOHO) study
    Jihyung Hong
    Personal Social Services Research Unit, London School of Economics and Political Science, Houghton Street, London, WC2A 2AE, UK
    BMC Psychiatry 12:218. 2012
  2. ncbi request reprint The effectiveness of olanzapine in treatment-refractory schizophrenia when patients are nonresponsive to or unable to tolerate clozapine
    - Dossenbach MRK
    Lilly Area Medical Center Vienna, Vienna, Austria
    Clin Ther 22:1021-34. 2000
  3. ncbi request reprint Double-blind, randomized comparison of olanzapine versus fluphenazine in the long-term treatment of schizophrenia
    Martin R K Dossenbach
    Lilly Area Medical Center, Eli Lilly, Barichgasse 40 42, Vienna A 1030, Austria
    Prog Neuropsychopharmacol Biol Psychiatry 28:311-8. 2004
  4. ncbi request reprint Long-term antipsychotic monotherapy for schizophrenia: disease burden and comparative outcomes for patients treated with olanzapine, quetiapine, risperidone, or haloperidol monotherapy in a pan-continental observational study
    Martin Dossenbach
    Eli Lilly and Co, GmbH, Vienna, Austria
    J Clin Psychiatry 69:1901-15. 2008
  5. ncbi request reprint Olanzapine versus chlorpromazine in the treatment of schizophrenia: a pooled analysis of four 6-week, randomized, open-label studies in the Middle East and North Africa
    Martin Dossenbach
    Eli Lilly Austria Medical Department, Eli Lilly Regional GmbH, Vienna, Austria
    J Clin Psychopharmacol 27:329-37. 2007
  6. ncbi request reprint Response and relapse in patients with schizophrenia treated with olanzapine, risperidone, quetiapine, or haloperidol: 12-month follow-up of the Intercontinental Schizophrenia Outpatient Health Outcomes (IC-SOHO) study
    Martin Dossenbach
    Eli Lilly and Company, Ges m b H, Vienna, Austria
    J Clin Psychiatry 66:1021-30. 2005
  7. ncbi request reprint The intercontinental schizophrenia outpatient health outcomes (ic-soho) study: baseline clinical and functional characteristics and antipsychotic use patterns in the central and eastern europe (cee) region
    Frans A Korb
    Clinical Research Physician Neuroscience, Eli Lilly Regional Operations, Vienna, Austria
    Psychiatr Danub 15:163-74. 2003

Collaborators

Detail Information

Publications7

  1. pmc Clinical consequences of switching from olanzapine to risperidone and vice versa in outpatients with schizophrenia: 36-month results from the Worldwide Schizophrenia Outpatients Health Outcomes (W-SOHO) study
    Jihyung Hong
    Personal Social Services Research Unit, London School of Economics and Political Science, Houghton Street, London, WC2A 2AE, UK
    BMC Psychiatry 12:218. 2012
    ..This study aimed to examine the impact of switching from olanzapine to risperidone and vice versa on clinical status and tolerability outcomes in outpatients with schizophrenia in a naturalistic setting...
  2. ncbi request reprint The effectiveness of olanzapine in treatment-refractory schizophrenia when patients are nonresponsive to or unable to tolerate clozapine
    - Dossenbach MRK
    Lilly Area Medical Center Vienna, Vienna, Austria
    Clin Ther 22:1021-34. 2000
    ....
  3. ncbi request reprint Double-blind, randomized comparison of olanzapine versus fluphenazine in the long-term treatment of schizophrenia
    Martin R K Dossenbach
    Lilly Area Medical Center, Eli Lilly, Barichgasse 40 42, Vienna A 1030, Austria
    Prog Neuropsychopharmacol Biol Psychiatry 28:311-8. 2004
    ..The study indicates that olanzapine has advantages in both efficacy and safety compared to fluphenazine; however, the small sample size limits our ability to draw definitive conclusions...
  4. ncbi request reprint Long-term antipsychotic monotherapy for schizophrenia: disease burden and comparative outcomes for patients treated with olanzapine, quetiapine, risperidone, or haloperidol monotherapy in a pan-continental observational study
    Martin Dossenbach
    Eli Lilly and Co, GmbH, Vienna, Austria
    J Clin Psychiatry 69:1901-15. 2008
    ..This article describes disease burden and patient outcomes, with an emphasis on the comparative effectiveness and tolerability of antipsychotic monotherapy...
  5. ncbi request reprint Olanzapine versus chlorpromazine in the treatment of schizophrenia: a pooled analysis of four 6-week, randomized, open-label studies in the Middle East and North Africa
    Martin Dossenbach
    Eli Lilly Austria Medical Department, Eli Lilly Regional GmbH, Vienna, Austria
    J Clin Psychopharmacol 27:329-37. 2007
    ..09 +/- 1.11; chlorpromazine, 0.72 +/- 2.04; P = 0.042). This analysis suggests that, compared with chlorpromazine, olanzapine may be more efficacious and have a more favorable tolerability profile in treating patients with schizophrenia...
  6. ncbi request reprint Response and relapse in patients with schizophrenia treated with olanzapine, risperidone, quetiapine, or haloperidol: 12-month follow-up of the Intercontinental Schizophrenia Outpatient Health Outcomes (IC-SOHO) study
    Martin Dossenbach
    Eli Lilly and Company, Ges m b H, Vienna, Austria
    J Clin Psychiatry 66:1021-30. 2005
    ..The study also examined other measures of clinical effectiveness and tolerability...
  7. ncbi request reprint The intercontinental schizophrenia outpatient health outcomes (ic-soho) study: baseline clinical and functional characteristics and antipsychotic use patterns in the central and eastern europe (cee) region
    Frans A Korb
    Clinical Research Physician Neuroscience, Eli Lilly Regional Operations, Vienna, Austria
    Psychiatr Danub 15:163-74. 2003
    ..Once completed, the IC-SOHO study will add further to this knowledge base...